TheraPPi Bioscience, MPC Therapeutics SA and dEEgtal awarded by the FIF
Share this article
The Fongit Innovation Fund (FIF) has awarded three Geneva-based life sciences projects for their groundbreaking innovations.
A seed loan of CHF 100,000 was awarded to TheraPPI Bioscience, whose technology tackles drug-resistant cancers drug-resistant cancers and uncurable rare diseases. A second of CHF 100,000 was granted to MPC Therapeutics SA, a spin-off from the University of Geneva, for its work on combating degenerative diseases through cellular rejuvenation. A grant of CHF 50,000 was also awarded to dEEgtal, a University of Geneva project, for its innovation using artificial intelligence to improve the diagnosis of epilepsy.
TheraPPi Bioscience awarded CHF 100,000 seed capital loan
TheraPPI Bioscience has been awarded a FIF seed loan of CHF 100,000 for its innovative work on modifying protein interactions in order to drug-resistant cancers and uncurable rare diseases. diseases. TheraPPI Bioscience’s technology was initially developed CRCL (Université Claude Bernard Lyon 1, Inserm, Centre Léon Bérard and CNRS) in Lyon, France. Lyon, France.
Seed loan of CHF 100,000 granted to MPC Therapeutics SA
MPC Therapeutics SA, a spin-off from the University of Geneva based in Plan-les-Ouates, is working to combat cancer and degenerative diseases by improving the efficacy of cellular therapies through cell rejuvenation. FIF has granted MPC Therapeutics SA a seed loan of CHF 100,000 for its innovative approach using proprietary, first-in-class small molecules specifically designed to target mitochondria and initiate metabolic reprogramming.
CHF 50,000 grant awarded to dEEgtal
Epilepsy affects almost 1% of the world’s population. Despite encouraging in its treatment, epilepsy remains difficult to diagnose. Supported by the University of Geneva’s Science Innovation Hub, dEEGtal draws on recent advances in artificial intelligence to help doctors diagnose epilepsy more accurately.
About the FIF
The FONGIT Innovation Fund (FIF) promotes the innovation and development of promising companies in the Canton of Geneva working towards the Development Goals (SDGs). FIF is supported by the State of Geneva Fondation Genevoise pour l’Innovation Technologique (FONGIT), the Geneva Chamber of Commerce (CCIG), the United Nations International Trade (ITC) and the United Nations Environment Agency.
The FIF supports innovative technology start-ups, scale-ups and small and medium-sized enterprises (SMEs) at various stages of their development at different stages of their development with three types of financing options: the Fongit Grant (up to CHF 50,000), the Fongit Seed Loan (up to CHF 100,000) and the Fongit Growth Loan (up to CHF 400,000).
⏰ Next deadline for FIF: 17 November 2023
Source: FONGIT press release
📸 dEEgtal team: Stefano Gallotto, PhD; HUG consultant Prof. Margitta Seeck; Eric Ménétré, PhD.